Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide

NCT07777575 · Recruiting

Last updated 2026-09-22

This clinical trial is testing whether resistance training can help prevent muscle loss in adults with obesity who are receiving tirzepatide treatment.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 150 people Planned (estimated).

Who can join Ages 18–60 · all sexes

Timeline Started 2026-09 · est. completion 2027-05

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT07777575 ↗

Description as written by the study sponsor.

Incretin-based pharmacotherapies induce significant weight loss and represent a paradigm shift in obesity treatment. However, particularly fast weight loss may be accompanied by a significant loss of muscle mass, which is associated with a reduced metabolic rate at rest and during physical activity, increased insulin resistance, limited mobility, and potential long-term adverse effects. The aim of this clinical trial is to examine the effects of resistance training versus standard of care on contractile thigh muscle volume in patients receiving the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists 'tirzepatide'.

Treatments tested

Dual GIP/GLP-1 Receptor Agonist Tirzepatide Drug

Tirzepatide will be titrated to a maximum tolerated dose of up to 10 mg/week (+2.5 mg/week every 4 weeks) and accomponied by regular individual diet and physical activity counseling
Resistance Training Behavioral

Low-volume, high-intensity resistance training on 3 days/week

Main thing measured	Change in contractile thigh muscle volume (mL), as assessed by magnetic resonance imaging (MRI)
Sponsor	Technical University of Munich
Conditions studied	Obesity (BMI>30)
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07777575 ↗